"Myasthenia Gravis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
| Descriptor ID |
D009157
|
| MeSH Number(s) |
C10.114.656 C10.668.758.725 C20.111.258.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myasthenia Gravis".
Below are MeSH descriptors whose meaning is more specific than "Myasthenia Gravis".
This graph shows the total number of publications written about "Myasthenia Gravis" by people in this website by year, and whether "Myasthenia Gravis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2001 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myasthenia Gravis" by people in Profiles.
-
Bril V, Berkowicz T, Szczudlik A, Nicolle MW, Bednarik J, Hon P, Vaitkus A, Vu T, Rozsa C, Magnus T, Panczel G, Toomsoo T, Pasnoor M, Mozaffar T, Freimer M, Reuner U, V?csei L, Souayah N, Levine T, Pascuzzi RM, Dalakas MC, Rivner M, Griffin R, Coll MQ, Mondou E. Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial. Muscle Nerve. 2025 Jan; 71(1):43-54.
-
Dalakas MC. Advances in the therapeutic algorithm for myasthenia gravis. Nat Rev Neurol. 2023 07; 19(7):393-394.
-
Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022 07; 18(7):691-701.
-
Dalakas MC, Meisel A. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Rev Neurother. 2022 04; 22(4):313-318.
-
Stathopoulos P, Dalakas MC. Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. Neurotherapeutics. 2022 04; 19(3):691-710.
-
Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020 10; 33(5):545-552.
-
Balabbigari N, Purewal J, Sakul N, Purewal A, Kankanala V, Califano T. Cranial Nerve IX and X Weakness: An Unusual Initial Presentation of Myasthenia Gravis. Am J Case Rep. 2020 Aug 10; 21:e923750.
-
Dehbashi S, Hamouda D, Shanina E. Co-occurrence of multiple sclerosis and myasthenia gravis: A case report and review of immunological theories. Mult Scler Relat Disord. 2019 Sep; 34:135-136.
-
Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019 02; 15(2):113-124.
-
Aktas A, Rojas E, Parikh HA, Pergament K. Myasthenia gravis crisis coinciding with asthma exacerbation in a patient with recent heroin use: three causes of acute hypercarbic respiratory failure. BMJ Case Rep. 2018 Oct 07; 2018.